According to filings with the U.S. Securities and Exchange Commission, Lokavant is raising $21,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Rohit Nambisan played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Lokavant
Lokavant is a clinical intelligence company that improves the time, cost, and quality of trial execution through its data-driven analytics platform. Lokavants platform aggregates and integrates real-time data from disparate trial data sources, and powers advanced analytics enabled by its compendium of proprietary trial data. The suite of applications built on the platform allows study teams to proactively manage their studies, and surfaces insights, driving efficiencies in scientific and operational use cases such as risk-based monitoring, milestone tracking, trial planning and benchmarking, medical monitoring, and more.

To learn more about Lokavant, visit http://www.lokavant.com/

Contact:
Rohit Nambisan, Chief Executive Officer
646-802-9886

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved